Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
BiomX has announced a collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease (IBD) using its XMarker discovery platform. This collaboration follows their first in September 2020, demonstrating ongoing partnership efforts in IBD research. BiomX aims to leverage its technology to help delineate patient segments based on their microbiome, potentially enhancing treatment specificity. The agreement includes research payments and an option for Boehringer Ingelheim to obtain exclusive rights to any discovered biomarkers, while BiomX retains rights for companion diagnostics.
BiomX (AMEX: PHGE) announced the dosing of its first two patients in a Phase 1b/2a study evaluating BX004 for treating chronic respiratory infections in cystic fibrosis patients. This clinical milestone is aimed at assessing BX004's safety and clinical activity against antibiotic-resistant P. aeruginosa. Results from Part 1 are expected in Q3 2022, followed by Part 2, which involves a larger cohort. The company received a $5 million award from the Cystic Fibrosis Foundation to support its development efforts.
BiomX (AMEX: PHGE) announces a corporate restructuring plan to enhance capital resources, cutting headcount by 50%. The cash runway is extended to at least mid-2024, with $55.7 million in cash and a $15 million debt facility reported as of March 31, 2022. The Cystic Fibrosis (CF) program is progressing, with initial results from the Phase 1b/2a study of BX004 expected in Q3 2022. However, the Atopic Dermatitis program will face delays due to the restructuring.
BiomX (NYSE American: PHGE) announced the publication of a scientific paper on the Exodus algorithm, enhancing the identification of genetically-related microorganisms. The Exodus algorithm improves the quantification of pooled genomes, achieving median error rates between 0% and 0.21%. Notably, the algorithm recorded no false negatives, indicating high accuracy even with low-abundance genomes. This advancement is expected to optimize the detection of virus variants and aid in the analysis of various genomic projects.
BiomX (PHGE) has made significant strides in its pipeline, particularly in treating cystic fibrosis (BX004) and atopic dermatitis (BX005). The Phase 1b/2a trial for BX004 is set to begin, with initial results expected by Q3 2022. The IND for BX005 has been approved, with data readouts anticipated in Q4 2022. Financially, the company reported a cash balance of $55.7 million as of March 31, 2022, down from $63.1 million, primarily due to operating expenses. Despite a net loss of $8.2 million, the cash runway is projected to last through 2023.
BiomX Inc. (NYSE American: PHGE) will host a virtual key opinion leader webinar on May 12, 2022, at 11:00 AM EDT to discuss BX004, a phage therapy aimed at treating Pseudomonas Aeruginosa infections in cystic fibrosis patients. The FDA cleared BX004 for a Phase 1b/2a trial in September 2021, with initial data expected in Q3 2022. Key Opinion Leaders Dr. Dave Nichols and Dr. Saima Aslam will present, followed by BiomX CEO Jonathan Solomon. Registration is available on BiomX's website.
BiomX (NYSE American: PHGE) will host a conference call on May 11, 2022, at 8:00 a.m. EDT to report first quarter 2022 financial results and provide business updates. BiomX is a clinical-stage microbiome company that focuses on developing natural and engineered phage therapies to combat chronic diseases, including cystic fibrosis and colorectal cancer. Interested parties can participate via a dedicated dial-in or through a live audio webcast available on the company’s website.
BiomX (NYSE: PHGE) reported its financial results for Q4 and the full year 2021, revealing a cash position of $63.1 million, up from $57.1 million in 2020. The company anticipates major clinical data readouts in 2022 for its cystic fibrosis (BX004) and atopic dermatitis (BX005) therapies. BiomX’s current cash runway supports operations through 2023, with potential for extension to mid-2024 via venture debt. The net loss for 2021 stood at $36.2 million, marking an increase from $30.1 million in 2020. A conference call is scheduled for today at 8:00 am ET.
BiomX Inc. (NYSE American: PHGE) has announced a conference call scheduled for March 30, 2022, at 8:00 a.m. EDT to discuss its fourth quarter and full year 2021 financial results along with business updates. The company specializes in developing natural and engineered phage therapies targeting bacteria linked to chronic diseases like cystic fibrosis and colorectal cancer. Investors can access the live webcast via biomx.com.
BiomX (NYSE American: PHGE) has announced that CEO Jonathan Solomon will present at three notable conferences in 2022. These include the Aegis Virtual Conference on February 24, the Chardan 4th Annual Microbiome Medicines Summit on March 1, and the Oppenheimer & Co. 32nd Annual Healthcare Conference on March 17. The presentations will highlight the company's development of innovative phage therapies targeting pathogenic bacteria related to various chronic diseases. Live webcasts will be available on BiomX's website.